Cover Image
市場調查報告書

體外診斷 (IVD)的全球市場:2016年∼2026年

In Vitro Diagnostics World Market 2016-2026: Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose, Infectious Diseases, Rapid Cardiac Market, Cholesterol & Pregnancy Testing

出版商 Visiongain Ltd 商品編碼 206670
出版日期 內容資訊 英文 166 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
體外診斷 (IVD)的全球市場:2016年∼2026年 In Vitro Diagnostics World Market 2016-2026: Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose, Infectious Diseases, Rapid Cardiac Market, Cholesterol & Pregnancy Testing
出版日期: 2016年08月11日 內容資訊: 英文 166 Pages
簡介

本報告提供全球體外診斷 (IVD) 市場相關調查分析,概要,全球市場,次市場,主要國家的市場分析,主要企業,SWOT、STEP分析等系統性資訊。

第1章 報告概要

第2章 簡介

  • 所謂IVD檢驗
  • IVD的分類
  • IVD檢驗的種類

第3章 全球IVD市場

  • IVD市場
  • 全球IVD市場預測
  • IVD產業趨勢預測

第4章 IVD次市場

  • 全球照護現場 (POC) IVD市場
  • 全球臨床化學IVD市場
  • 全球免疫化學IVD市場
  • 全球血液IVD市場
  • 全球微生物IVD次市場
  • 遺傳基因檢驗

第5章 主要國家的IVD市場

  • 全球IVD市場各地區明細
  • 全球IVD市場主要國家市場
  • 美國的IVD市場預測
  • 日本的IVD市場
  • EU5個國家的IVD市場
  • 金磚四國

第6章 IVD市場主要企業

  • 分散市場
  • IVD市場:主要企業的明細
  • Roche的優勢持續
  • Danaher:強力的競爭企業
  • Siemens:高度多樣化的企業
  • Abbott Laboratories大的貢獻
  • Thermo Fisher Scientific收購Life Technology
  • Agilent Technologies Inc.
  • IVD市場小企業

第7章 IVD市場SWOT、STEP分析

  • IVD:產業趨勢
  • IVD市場優勢
  • 弱點
  • 機會
  • 威脅
  • STEP分析

第8章 專家的見解

第9章 調查的結論

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0136

Title:
IN VITRO DIAGNOSTICS WORLD MARKET 2016-2026
Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing.

The In Vitro Diagnostics World Market 2016-2026: Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Genetic Testing, Point of Care Diagnostics, Blood Glucose Testing, Infectious Diseases Testing, Rapid Cardiac Market Testing, Cholesterol Testing, Pregnancy Testing report assesses the global market for IVDs. The market is first split and forecasted by submarket.

Six main submarkets are covered, these are the:

  • Point-of-care diagnostics (PoC)
  • Clinical chemistry
  • Immunochemistry
  • Haematology
  • Microbiology
  • Genetic testing

The leading submarket in the IVD industry at present and throughout the next decade will be point-of-care diagnostics. This submarket is further subdivided into more specific tests. Blood glucose testing accounted for over half of the revenue PoC testing made in 2015 due to the rise in prevalence of diabetes.

What are the prospects in the leading regions and countries?

In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:

  • US
  • Japan
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • China
  • India
  • Brazil
  • Russia
  • Rest of the World

The US, Japan and China were the 1st 2nd and 3rd leading national markets in 2015 and each will retain its place over the next 10 years. India will be the fastest growing national market from 2015-2026 with China close behind.

Our new report discusses issues and events affecting the IVD market. You will find discussions, including qualitative analyses on:

  • The global IVD market
  • The IVD market divided by submarket including; point-of-care, clinical chemistry, haematology, immunochemistry, microbiology and genetic testing
  • The challenges facing the market, such as the US excise tax on medical devices
  • The latest merger & acquisition activity amongst industry leaders
  • 11 different national markets including the ‘EU5' and ‘BRIC' nations

Visiongain predicts that the demand for IVDs will increase in line with the rise in both incidence and prevalence of chronic and infectious diseases. Health professionals will recognise that if these diseases can be diagnosed at the earliest stage possible, then damage to the individual can be minimised in addition to a reduction of later costs to healthcare systems. IVDs will be able to stem the economic and clinical costs of chronic and infectious disease.

The drive to provide patients with diagnostic testing options that are more accurate, easy-to-use and convenient will sustain growth in the IVD market during the forecast period of this report.

Our 166 page report provides 38 tables and 72 figures covering 6 different IVD submarkets. 11 individual national markets are covered in addition to coverage of the leading companies in the industry. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, a primary interview, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Introduction to the IVD Industry and Market
  • 1.2. Main Report Findings
  • 1.3. This Study Provides the Following Knowledge
  • 1.4. Why You Should Read This Report
  • 1.5. How This Report Delivers
  • 1.6. Main Questions Answered by This Study
  • 1.7. Who is This Study For?
  • 1.8. Research Methods and Analysis
  • 1.9. Frequently Asked Questions (FAQ)
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction

  • 2.1. What are In Vitro Diagnostic (IVD) Tests?
  • 2.2. Classifying In Vitro Diagnostics
    • 2.2.1. The US Classification
    • 2.2.2. The European Commision (EC) Classification
    • 2.2.3. Regulatory Issues in the IVD Market
      • 2.2.3.1. Regulation of IVD Tests
      • 2.2.3.2. Lack of Clarity Can be Costly
  • 2.3. What are the Different Types of IVD Tests?
    • 2.3.1. Point of care Diagnostics - The Most Prominent Type of IVD
    • 2.3.2. Clinical Chemistry is Increasing in Complexity
    • 2.3.3. Microbiology
      • 2.3.3.1. Regulatory Differences with IVD Microbiology Tests
    • 2.3.4. Haematology
    • 2.3.5. Immunochemistry
    • 2.3.6. Genetic Testing

3. The Global In Vitro Diagnostics Market, 2016-2026

  • 3.1. In Vitro Diagnostics Market in 2015
  • 3.2. Global IVD Market Forecast, 2016-2026: Three Submarkets Dominate
  • 3.3. Expected IVD Industry Trends Over 2016-2026
    • 3.3.1. Advances in Technology Driving the IVD Market
    • 3.3.2. A Shift towards Decentralisation Healthcare
    • 3.3.3. Increased Awareness of the Need for IVD Tests

4. In Vitro Diagnostics Submarkets, 2016-2026

  • 4.1. The Global Point-of-Care IVD Market, 2016-2026: A Revolution in the Making
    • 4.1.1. POC Diagnostics Market, 2015
    • 4.1.2. POC Diagnostics: Market Forecast, 2016-2026
    • 4.1.3. POC Diagnostics: Market Trends, 2016-2026
      • 4.1.3.1. New Tests Targeting Biomarkers Will Be Crucial
      • 4.1.3.2. Competition Driving Consolidation and Product Innovation
      • 4.1.3.3. Infectious Diseases Prompting Growth of POC
      • 4.1.3.4. Other Factors Influencing the POC Segment
  • 4.2. The Global Clinical Chemistry IVD Market, 2016-2026
    • 4.2.1. Clinical Chemistry Market Forecast, 2016-2026
    • 4.2.2. Clinical Chemistry Market Trends, 2016-2026
  • 4.3. The Global Immunochemistry IVD Market, 2016-2026
    • 4.3.1. Immunochemistry Market Forecast, 2016-2026
    • 4.3.2. Immunochemistry Market Trends, 2016-2026
      • 4.3.2.1. Immunoassays and Automated Systems Prompting Market Growth
      • 4.3.2.2. Emerging Markets Showing Strong Growth and Opportunities
  • 4.4. The Global Haematology IVD Market, 2016-2026
    • 4.4.1. Haematology Market Forecast, 2016-2026
    • 4.4.2. Haematology Market Trends, 2016-2026
  • 4.5. The Global Microbiology IVD Submarket, 2016-2026
    • 4.5.1. Microbiology Market Forecast, 2016-2026
    • 4.5.2. Microbiology Market Trends, 2016-2026
  • 4.6. Genetic testing - The Future of the Industry
    • 4.6.1. Genetic Testing Market Forecast, 2016-2026
    • 4.6.2. Genetic Testing Market Trends, 2016-2026
      • 4.6.2.1. Cytogenetic tests to Drive Market Growth
      • 4.6.2.2. Direct-To-Consumer (DTC) Genetic Screening
      • 4.6.2.3. Theranostics: Targeting Unmet Needs through DNA Tests

5. Leading National IVD Markets, 2016-2026

  • 5.1. Regional Breakdown of the Global IVD Market, 2015
  • 5.2. Leading National Markets for the Global IVD Market, 2016-2026
  • 5.3. The US IVD Market Forecast, 2016-2026: Still the Global Leader
    • 5.3.1. Increased Levels of Molecular Testing in the US
    • 5.3.2. Increased Use of Mobile Applications
    • 5.3.3. Obamacare and the Medical Device Excise Tax
  • 5.4. The Japanese IVD Market 2016-2026
  • 5.5. The EU5. Nations IVD Market, 2016-2026
    • 5.5.1. Germany IVD Market, 2016-2026
    • 5.5.2. The French IVD Market, 2012-2026
    • 5.5.3. The UK IVD Market, 2016-2026
    • 5.5.4. The Spanish IVD Market, 2016-2026
    • 5.5.5. The Italian IVD Market, 2016-2026
  • 5.6. The BRIC Nations
    • 5.6.1. The Brazilian IVD Market, 2016-2026
    • 5.6.2. The Russian IVD Market, 2016-2026
    • 5.6.3. The Indian IVD Market, 2016-2026
    • 5.6.4. The Chinese IVD Market, 2016-2026

6. Leading Companies in the IVD Market, 2016

  • 6.1. A Fragmented Market with a Few Dominant Major Players
  • 6.2. IVD Market Leaders Breakdown
  • 6.3. Roche Continues to Dominate
    • 6.3.1. Sales and Recent Performance Analysis, 2015
      • 6.3.1.1. Roche Diagnostics - Driven by Immunodiagnostic Products
  • 6.4. Danaher - A Strong Competitor in the IVD Market
    • 6.4.1. Sales and Performance Analysis, 2015
      • 6.4.1.1. Life sciences & Diagnostics - Danaher's Main Source of Revenue
  • 6.5. Siemens - A Highly Diversified Company
    • 6.5.1. Sales and Recent Performance Analysis
      • 6.5.1.1. Siemens Healthcare Sector
  • 6.6. Abbott Laboratories Make a Prominent Contribution
    • 6.6.1. Sales and Recent Performance Analysis, 2015
      • 6.6.1.1. The Abbott Diagnostics Segment - Alere Acquisition Proving Troublesome
  • 6.7. Thermo Fisher Scientific Acquires Life Technologies
  • 6.8. Agilent Technologies Inc.
  • 6.9. Smaller Companies in the IVD Market, 2016
    • 6.9.1. Johnson & Johnson - The World's Largest Med Tech Company
    • 6.9.2. Myriad Genetics - Specialist Molecular Diagnostics
    • 6.9.3. Horizon Discovery - A World Leader in Gene-Editing

7. SWOT and STEP Analysis of the IVD Market, 2016

  • 7.1. In Vitro Diagnostics: Industry Trends
  • 7.2. Strengths of the IVD Market, 2016
    • 7.2.1. Patient Demographics Will be a Major Driver
    • 7.2.2. Innovation Will Continue
  • 7.3. Weaknesses
    • 7.3.1. Regulatory Board Approvals May be Problematic
    • 7.3.2. Reimbursement Issues Could Restrain Growth
  • 7.4. Opportunities
    • 7.4.1. Globalisation Creates a Wealth of Opportunity in Emerging Economies
    • 7.4.2. Molecular Diagnostics Will have Increased Prominence
  • 7.5. Threats
    • 7.5.1. Medical Device Excise Tax in the US
    • 7.5.2. Convergence
  • 7.6. STEP Analysis
    • 7.6.1. Social Factors
    • 7.6.2. Technological Factors
    • 7.6.3. Economic Factors
    • 7.6.4. Political Factors

8. Research Interviews

  • 8.1. Interview with Horizon Discovery, a Gene-Editing Company
    • 8.1.1. On Horizon Discovery and the IVD Products Which They Offer
    • 8.1.2. On the Challenges of Developing IVDs
    • 8.1.3. On IVDs in the Future

9. Conclusions from the Research

  • 9.1. Overview of the IVD Market
  • 9.2. Submarket Breakdown: Point of Care Testing Will be the Biggest Driver
  • 9.3. National IVD Market Outlook, 2016-2026
  • 9.4. Leading Companies in the Global IVD Market
  • 9.5. Future Outlook and Concluding Remarks
  • 9.6. Associated Visiongain Reports
  • 9.7. Visiongain Report Sales Order Form
  • 9.8. About Visiongain
  • 9.9. Report Evaluation Form

List of Tables

  • Table 1.1: Global IVD Market Forecasts, 2016-2026: Revenue ($bn), Market Share (%), Annual Growth Rate (%) and CAGR (%)
  • Table 2.1: Advantages and Disadvantages of POC Diagnostics, 2016
  • Table 3.1: IVD Global Market Revenues ($bn) and Market Shares (%) by Sector, 2015
  • Table 3.2: Global IVD Market Forecasts, 2016-2026: Revenue ($bn), Market Share (%), Annual Growth Rate (%) and CAGR (%)
  • Table 4.1: POC Diagnostics Market Shares (%) & Revenues ($bn) by Test, 2015
  • Table 4.2: Point-of-Care (POC) Diagnostics Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 4.3: Clinical Chemistry Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 4.4: Immunochemistry IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 4.5: Haematology IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 4.6: Microbiology IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 4.7: Genetic Testing IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.1: IVD Market Revenues ($bn) and Market Shares (%) by Country, 2015
  • Table 5.2: IVD Market Forecasts, 2016-2026: Revenue ($bn), Market Share (%), Annual Growth Rate (%) and CAGR (%)
  • Table 5.3: The US IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.4: The Japanese IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.5: The EU5 IVD Market Forecast, 2016-2026: Revenue ($bn), EU5 Market Share (%), AGR (%) and CAGR (%)
  • Table 5.6: The German IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.7: The French IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.8: The UK IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.9: The Spanish IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.10: The Italian IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.11: The BRIC IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.12: The Brazilian IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.13: The Russian IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.14: The Indian IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 5.15: The Chinese IVD Market Forecast, 2016-2026: Revenue ($bn), Market Share (%), AGR (%) and CAGR (%)
  • Table 6.1: Leading Companies in the IVD Market, Revenues ($bn) and Market Shares (%), 2015
  • Table 6.2: Leading Companies in the IVD Market, Revenues ($bn) and Market Shares (%), 2015
  • Table 6.3: Roche Diagnostics Product Lines: Revenues ($bn), Revenue Share (%) and Growth (%), 2015
  • Table 6.4: Danaher Total Revenues ($bn) and Revenue Shares (%) by Business Segments, 2015
  • Table 6.5: Siemens Revenues ($bn) & Revenue Shares (%) by Business Sectors, 2015
  • Table 6.6: Abbott Segment Revenues ($bn) and Revenue Shares (%), 2015
  • Table 6.7: Thermo Fisher Scientific Historical Sales: Revenue ($bn), AGR (%), 2010-2015
  • Table 6.8: Thermo Fisher Scientific Segment Breakdown: Revenue ($bn) and Revenue Share (%), 2015
  • Table 6.9: Agilent Technologies Revenues ($bn) and Revenue Shares (%), by Business Group, 2015
  • Table 6.10: Johnson & Johnson Major Medical Device Divisions: Revenues ($bn) and Revenue Share (%), 2015
  • Table 6.11: Myriad Genetics Revenues ($m) and Revenue Shares (%), by Business Segment, 2015
  • Table 7.1: SWOT Analysis of the Global IVD Market, 2016-2026

List of Figures

  • Figure 3.1: IVD Market Shares (%) by Submarket, 2015
  • Figure 3.2: IVD Market Shares (%) by Submarket, 2020
  • Figure 3.3: IVD Market Shares (%) by Submarket, 2026
  • Figure 3.4: Global IVD Market Revenue Forecast ($bn), 2016-2026
  • Figure 3.5: Global IVD Market AGR Forecast (%), 2016-2026
  • Figure 3.6: Global IVD Market: Drivers and Restraints, 2016-2026
  • Figure 4.1: POC Diagnostics Market Shares (%) by Test Type, 2015
  • Figure 4.2: Point-of-Care (POC) Diagnostics 2016-2026: Revenue Forecast ($bn)
  • Figure 4.3: Point-of-Care (POC) Diagnostics 2016-2026: AGR Forecast (%)
  • Figure 4.4: Point-of-Care (POC) Diagnostics Drivers and Restraints, 2016-2026
  • Figure 4.5: Clinical Chemistry Diagnostics 2016-2026: Revenue Forecast ($bn)
  • Figure 4.6: Clinical Chemistry Diagnostics 2016-2026: AGR Forecast (%)
  • Figure 4.7: Clinical Chemistry Drivers and Restraints, 2016-2026
  • Figure 4.8: Immunochemistry IVD 2016-2026: Revenue Forecast ($bn)
  • Figure 4.9: Immunochemistry IVD 2016-2026: AGR Forecast (%)
  • Figure 4.10: Immunochemistry Drivers and Restraints, 2016-2026
  • Figure 4.11: Haematology IVD 2016-2026: Revenue Forecast ($bn)
  • Figure 4.12: Haematology IVD 2016-2026: AGR Forecast (%)
  • Figure 4.13: Haematology Drivers and Restraints, 2016-2026
  • Figure 4.14: Microbiology IVD 2016-2026: Revenue Forecast ($bn)
  • Figure 4.15: Microbiology IVD 2016-2026: AGR Forecast (%)
  • Figure 4.16: Microbiology Drivers and Restraints, 2016-2026
  • Figure 4.17: Genetic Testing IVD 2016-2026: Revenue Forecast ($bn)
  • Figure 4.18: Genetic Testing IVD 2016-2026: AGR Forecast (%)
  • Figure 4.19: Genetic Testing Drivers and Restraints, 2016-2026
  • Figure 5.1: National IVD Market Shares (%), 2015
  • Figure 5.2: National IVD Market Shares (%), 2020
  • Figure 5.3: National IVD Market Shares (%), 2026
  • Figure 5.4: The US IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.5: The US IVD AGR Forecast (%), 2016-2026
  • Figure 5.6: US IVD Market Drivers and Restraints, 2016-2026
  • Figure 5.7: The Japanese IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.8: The Japanese IVD AGR Forecast (%), 2016-2026
  • Figure 5.9: Japanese IVD Market Drivers and Restraints, 2016-2026
  • Figure 5.10: EU5 IVD Market Shares (%) by Country, 2015
  • Figure 5.11: EU5 IVD Market Shares (%) by Country, 2020
  • Figure 5.12: EU5 IVD Market Shares (%) by Country, 2026
  • Figure 5.13: EU5 IVD Market Drivers and Restraints, 2016-2026
  • Figure 5.14: The German IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.15: The German IVD AGR Forecast (%), 2016-2026
  • Figure 5.16: The French IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.17: The French IVD AGR Forecast (%), 2016-2026
  • Figure 5.18: The UK IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.19: The UK IVD AGR Forecast (%), 2016-2026
  • Figure 5.20: The Spanish IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.21: The Spanish IVD AGR Forecast (%), 2016-2026
  • Figure 5.22: The Italian IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.23: The Italian IVD AGR Forecast (%), 2016-2026
  • Figure 5.24: The BRIC Nations IVD Market Shares (%) by Country, 2015
  • Figure 5.25: The BRIC Nations IVD Market Shares (%) by Country, 2020
  • Figure 5.26: The BRIC Nations IVD Market Shares (%) by Country, 2026
  • Figure 5.27: BRIC Nations IVD Market Drivers and Restraints, 2016-2026
  • Figure 5.28: The Brazilian IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.29: The Brazilian IVD AGR Forecast (%), 2016-2026
  • Figure 5.30: The Russian IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.31: The Russian IVD AGR Forecast (%), 2016-2026
  • Figure 5.32: The Indian IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.33: The Indian IVD AGR Forecast (%), 2016-2026
  • Figure 5.34: The Chinese IVD Revenue Forecast ($bn), 2016-2026
  • Figure 5.35: The Chinese IVD AGR Forecast (%), 2016-2026
  • Figure 6.1: Leading Companies in the IVD Market by Market Shares (%), 2015
  • Figure 6.2: Roche Revenue Shares (%) by Business Segment, 2015
  • Figure 6.3: Roche Diagnostics Product Lines: Revenue Shares (%), 2015
  • Figure 6.4: Danaher Revenue Shares (%) by Business Segment, 2015
  • Figure 6.5: Siemens Revenue Share (%), by Business Sectors, 2015
  • Figure 6.6: Abbott Revenue Shares (%), by Segment, 2015
  • Figure 6.7: Thermo Fishers Scientific Segment Revenue Shares (%), 2015
  • Figure 6.8: Agilent Technologies Revenue Shares (%), by Business Group, 2015
  • Figure 6.9: Johnson & Johnson Major Medical Device Divisions Revenue Share (%),
  • Figure 6.10: Myriad Genetics Revenue Shares (%) by Business Segment, 2015
  • Figure 9.1: The Global IVD Submarket Forecast Breakdown: Revenue ($bn), 2016-2026
  • Figure 9.2: National IVD Market Shares (%), 2015

Companies Listed

  • 3M
  • Abbott Laboratories
  • AbbVie
  • Adaltis
  • AdnaGen AG
  • Affymetrix
  • Agendia
  • Agilent
  • Akonni Biosystems
  • Alere
  • Amgen
  • Arkay
  • AssuraGen
  • Astute Medical
  • Atlas Genetics
  • Bayer
  • Beckman Coulter
  • Binding Site
  • Biohit HealthCare
  • bioMérieux
  • Bio-Rad
  • BioSystems
  • Bristol Myers-Squibb
  • CardioGenics
  • Celerus Diagnostics
  • Center for Devices and Radiological Health (CDRH) [part of US FDA]
  • Cepheid
  • Claros Diagnostics
  • Cognex
  • Compendia Bioscience
  • Corgenix
  • Crescendo Bioscience
  • Dako
  • Danaher
  • Daxor Corporation
  • Devicor Medical Products
  • DiaGenic
  • DiaSorin
  • Diaxonhit
  • Diazyme Laboratories
  • European Commission (EC)
  • European Diagnostic Manufacturers Association (EDMA)
  • European Medicines Agency (EMA)
  • Expression Diagnostics
  • Foundation for Innovative and New Diagnostics (FIND)
  • Fujirebio Diagnostics Inc.
  • Gene Chip Research Centre, Tianjin, China
  • Genentech
  • GenMark Diagnostics
  • Genomic Health
  • Gen-Probe
  • Gifu University
  • Glycominds
  • Hai Kang Life Corporation
  • Haplogen Genomics GmbH
  • HemoCue
  • Hoffman-La Roche
  • Hologic
  • Human Genetics Commission
  • Immucell
  • Immucor
  • Innogenetics
  • Innova Biotechnology Co.
  • Instrumentation Laboratory
  • Ipsogen
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • Japanese Ministry of Health and Welfare
  • Johnson & Johnson
  • Kreatech Diagnostics
  • Lab-21
  • LabIndia
  • Launch Diagnostics
  • Leica Microsystems
  • Life Technologies
  • LifeScan
  • Luminex
  • Med BioGene
  • Melanoma Diagnostics
  • Meridian Bioscience
  • Milagen
  • Mindray
  • Miraca Life Sciences
  • Myriad Genetics
  • Nanosphere
  • National Institute of Clinical Excellence (UK NICE)
  • Novartis
  • Onconome
  • Orion Genomics
  • Ortho Clinical Diagnostics
  • PathWorks Diagnostics
  • PerkinElmer
  • Pharmaceutical and Medical Devices Agency, Japan (PMDA)
  • Phillips
  • Polymedco
  • Qiagen
  • Quest Diagnostics
  • Radiometer Medical
  • Randox Laboratories
  • Response Biomedical
  • Roche
  • Rules-Based Medicine
  • Saladax Biomedical
  • Sanofi
  • SDIX
  • Sekisui Diagnostics
  • Sera Prognostics
  • SeraCare Life Sciences
  • Siemens
  • Span Diagnostics
  • St Jude Medical
  • Stago
  • STARLIMS Technologies
  • SterilMed
  • Suzhou Ribo Life Sciences
  • Synthes
  • Sysmex
  • Target Discovery
  • Targeted Diagnostics & Therapeutics
  • Tethys Bioscience
  • The Carlyle Group
  • Tocagen
  • Tosoh Bioscience
  • Transasia Bio Medicals
  • Trinity Biotech
  • United Nations (UN)
  • UroSens
  • US Food and Drug Administration (FDA)
  • VentriPoint
  • Verax Biomedical
  • Vermillion
  • ViiV Healthcare
  • World Health Organization (WHO)
Back to Top